# Emmaus Life Sciences, Inc. (EMMA)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/emmaus-life-sciences-inc/ JSON: https://steadybase.io/company/emmaus-life-sciences-inc.json Checked Nov 10, 2026. Latest filing read: Aug 14, 2026.

## Company

- Legal name: Emmaus Life Sciences, Inc.
- Ticker: EMMA (OTC)
- SEC CIK: 0000822370
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Torrance, CA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: emmausmedical.com
- Investor relations: https://ir.emmausmedical.com
- LinkedIn: https://www.linkedin.com/company/emmaus-life-sciences
- Next earnings date: Nov 14, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $12.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 31, 2026). Source: https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/0001193125-26-132925-index.html
- Operating income: $231,000 for the fiscal year ended Dec 31, 2025 (10-K filed Mar 31, 2026). Source: https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/0001193125-26-132925-index.html
- Net income: -$7.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 31, 2026). Source: https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/0001193125-26-132925-index.html
- SG&A: $11.1M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 31, 2026). Source: https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/0001193125-26-132925-index.html
- Employees: 33 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/emma-20251231.htm
- Shares outstanding: 70,188,263 as of Aug 11, 2026 (10-Q filed Aug 14, 2026). Source: https://www.sec.gov/Archives/edgar/data/822370/000119312526351833/0001193125-26-351833-index.html
- Auditor: Cbiz Cpas P.C., Costa Mesa, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/emma-20251231.htm

## Business

We are a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases.S. Food and Drug Administration, or FDA, to reduce the acute complications of sickle cell disease (“SCD”) in adult and pediatric patients five years of age and older.E, Qatar, Kuwait, Bahrain and Oman. Our a pplication for marketing authorization in the Kingdom of Saudi Arabia, or KSA, is pending.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/emma-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $12.5M | $231,000 | -$7.5M | $11.1M |
| Dec 31, 2024 | $16.7M | -$1.9M | -$6.5M | $16.7M |
| Dec 31, 2023 | $29.6M | $3.5M | -$3.7M | $23.5M |
| Dec 31, 2022 | $18.4M | -$6.6M | -$10.6M | $20.7M |
| Dec 31, 2021 | $20.6M | -$6.1M | -$15.9M | $19.3M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/emmaus-life-sciences-inc.json

## Officers and directors

- Willis C. Lee, CEO. LinkedIn: https://linkedin.com/in/willis-lee-9358424. Source: Form 4 filed Sep 2, 2026, https://www.sec.gov/Archives/edgar/data/822370/000119312526380023/0001193125-26-380023-index.htm
- Charles Stark, Chief Science Officer & Executive Vice President of Clinical Development and Medical Affairs, Clinical, Regulatory. Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/emma-20251231.htm
- Charles Stark, Pharm.D., Chief Science Officer & EVP of Clinical Development and Medical Affairs. Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/emma-20251231.htm
- Hiroko Huynh, Chief Accounting Officer. Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/emma-20251231.htm
- Jon Kuwahara, Director. Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/emma-20251231.htm
- Wei Peu Zen, Director. Source: 10-K filed Mar 31, 2026, https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/emma-20251231.htm

## Recent 8-K events

- Aug 14, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/822370/000121390026089912/ea0302099-8k_emmaus.htm
- May 15, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/822370/000121390026057828/ea0290896-8k_emmauslife.htm
- Apr 17, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/822370/000121390026045250/ea028688101-8k_emmauslife.htm
- Apr 14, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/822370/000121390026043577/ea0286215-8k_emmaus.htm
- Mar 31, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/822370/000121390026036886/ea0283899-8k_emmaus.htm
- Mar 4, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/822370/000121390026023644/ea0280016-8k_emmaus.htm
- Dec 31, 2025: Item 1.01, Entry into a material definitive agreement; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/822370/000121390025126728/ea027134801-8k_emmauslife.htm
- Dec 22, 2025: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 3.02, Unregistered sales of equity securities; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/822370/000121390025124513/ea0270289-8k_emmaus.htm
- Dec 19, 2025: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/822370/000121390025123836/ea0270178-8k_emmaus.htm
- Nov 14, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/822370/000121390025110878/ea0265516-8k_emmaus.htm

## Insider trades (Form 4)

- Aug 31, 2026: Willis C. Lee (CEO) bought 530,767 shares, about $18,126. Source: https://www.sec.gov/Archives/edgar/data/822370/000119312526380023/0001193125-26-380023-index.htm

## Latest filings

- 8-K filed Aug 14, 2026: https://www.sec.gov/Archives/edgar/data/822370/000121390026089912/ea0302099-8k_emmaus.htm
- 10-K filed Mar 31, 2026: https://www.sec.gov/Archives/edgar/data/822370/000119312526132925/emma-20251231.htm
- 10-Q filed Aug 14, 2026: https://www.sec.gov/Archives/edgar/data/822370/000119312526351833/emma-20260630.htm
- DEF 14A filed Oct 31, 2022: https://www.sec.gov/Archives/edgar/data/822370/000114036122039001/ny20005565x2_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/